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Abstract
Background: Fluoroquinolones are used with increasing frequency in children with a major risk of increasing the
emergence of FQ resistance. FQ use has expanded off-label for primary antibacterial prophylaxis or treatment of
infections in immune-compromised children and life-threatening multi-resistant bacteria infections. Here we
assessed the prescriptions of ciprofloxacin in a pediatric cohort and their appropriateness.
Methods: A monocenter audit of ciprofloxacin prescription was conducted for six months in a University hospital
in Paris. Infected site, bacteriological findings and indication, were evaluated in children receiving ciprofloxacin in
hospital independently by 3 infectious diseases consultants and 1 hospital pharmacist.
Results: Ninety-eight ciprofloxacin prescriptions in children, among which 52 (53.1%) were oral and 46 (46.9%)
parenteral, were collected. 45 children had an underlying condition, cystic fibrosis (CF) (21) or an innate or acquired
immune deficiency (24). Among CF patients, the most frequent indication was a broncho-pulmonary Pseudomonas
aeruginosa infection (20). In non-CF patient, the major indications were broncho-pulmonary (25), urinary (8), intra-
abdominal (7), operative site infection (5) and bloodstream/catheter (2/4) infection. 62.2% were microbiologically
documented. Twenty-three (23.4%) were considered “mandatory”, 48 (49.0%) “alternative” and 27 (27.6%)
“unjustified”.
Conclusion: In our university hospital, only 23.4% of fluoroquinolones prescriptions were mandatory in children,
especially in Pseudomonas aeruginosa healthcare associated infection. Looking to the ecological risk of
fluoroquinolones and the increase consumption in children population we think that a control program should be
developed to control FQ use in children. It could be done with the help of an antimicrobial stewardship team.
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Background
Fluoroquinolones (FQ) are licensed and widely indicated
for use in adults, owing to the agents’ broad-spectrum
antibacterial activity, their extensive tissue and intracel-
lular penetration, and their suitability for oral adminis-
tration. However, FQ use in pediatric patients has been
contraindicated by regulatory authorities in the United
States and the European Union, given the cartilage dam-
age that they may induce in juvenile animal models.
Nonetheless, FQ use in pediatric patients has increased
as shown in the United States, where approximately
520,000 prescriptions were written for children and ado-
lescents younger than 18 years in 2002 [1]. The safety of
fluoroquinolones is questioned in pediatric population [2].
Joint disorder and arthromyalgia could be as frequent as
8.3% [3-5]. In pediatric cystic fibrosis patients with acute
pulmonary exacerbation caused by P. aeruginosa [6], cip-
rofloxacin is initially administered intravenously at a dose
of 30 mg/kg/day divided every 8 h, followed by an oral ad-
ministration at 40 mg/kg/day divided every 12 h [7]. Sim-
ultaneously, FQ use has expanded off-label for primary
antibacterial prophylaxis or treatment of infections in
immune-compromised patients, infections due to life-
threatening multi-resistant bacteria, or salmonellosis or
shigellosis and cholangitis [1,6,8,9]. In 2004, ciprofloxacin
became the first fluoroquinolone agent approved by
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United States Food and Drug Administration for use in chil-
dren 1 through 17 years of age [10]. As suggested by several
studies [11-13] the increased use of fluoroquinolones will
subsequently contribute to the spread of resistance.
The aim of this observational study was to evaluate
the prescription of ciprofloxacin for pediatric infections.
Methods
A mono-center audit of ciprofloxacin prescription was
conducted between 1st December 2007 and 31st May
2008 at Necker-Enfants malades University hospital in
Paris. All consecutive pediatric patients (age <18 years)
admitted in our hospital, with fluoroquinolone pre-
scribed in hospital were included in this study. All pre-
scriptions were identified by pharmacy’s computer.
Descriptive data concerning patients’ characteristics (age,
underlying disease, current status, immune status such
as neutropenia <500/mm3 or immunosuppressive agent
use such as receiving 1 mg/kg/d prednisone for more
than 1 weeks or equivalent), the current ciprofloxacin
regimen (drug, indication and bacteriologic findings, jus-
tification for use, concomitant drugs administered) were
collected from patients’ medical documents.
Nosocomial infection was defined as an episode of in-
fection from patients who had been hospitalized for
48 hours or longer while health care-associated infection
was defined as from a patient at the time of hospital admis-
sion or within 48 hours of admission if the patient fulfilled
any of the following criteria (hemodialysis, intravenous
chemotherapy during the past 30 days, hospitalization for
at least two days during the past 90 days, home intraven-
ous therapy or wound care during the past 30 days).
Community-acquired infection was defined as an episode
of infection at the time of hospital admission or within the
48 hours after hospital admission for patients who did not
fit the criteria for a health care-associated infection [14].
The short-term side effects, such as nausea, abdom-
inal pain, diarrhea, vomiting, headache, rash or photo-
sensitivity, arthralgia and myalgia, were reported by
patient’s physician during the whole hospitalization
and reviewed twice weekly by our mobile infectious
diseases team (1 resident, 2 senior physicians and 1
professor in infectious diseases).
Appropriateness of ciprofloxacin prescription was retro-
spective performed separately by three experts in infec-
tious diseases and one hospital pharmacist. Prescriptions
were categorized as “mandatory, alternative or unjusti-
fied”. Ciprofloxacin use was considered “mandatory” if
susceptibility testing showed resistance to all beta-lactams
and TMP-SMX; susceptible only to FQ, or aminoglycoside
or colistin, or the ciprofloxacin was the only oral therapy
available.
Prescriptions were considered “alternative” in the set-
ting of ciprofloxacin use being indicated by clinical











Broncho-pulmonary n (%) 5 (45.4) 17 (70.8) 24 (38.6)
Urinary tract n (%) 2 (18.2) 2 (8.3) 4 (6.5)
Bloodstream/catheter
infection n (%)
0 (0) 0 (0) 2(3.2) /4
(6.5)
Infection of operative site n
(%)
0 (0) 0 (0) 5 (8.2)
Bone or joint n (%) 2 (18.2) 0 (0) 2 (3.2)
Intra-abdominal n (%) 1 (9.1) 0 (0) 6 (9.7)
Mediastinal$ n (%) 0 (0) 0 (0) 3 (4.8)
Cerebral n (%) 1 (9.1) 1 (4.2) 2 (3.2)
Endocarditis n (%) 0 (0) 0 (0) 2 (3.2)
Others n (%) 0 (0) 4£ (16.7) 8§ (12.9)
Total n (%) 11 (100) 24 (100) 62 (100)
£: 2 BCGitis and ocular infection and cutaneous infection each.
§: Fever in 8 immunocompromised children among whom 4 with
current neutropenia.
Among 98 children who received ciprofloxacin, one received it as prophylaxis
during orthopedic surgery (not shown in Table 1).
$: Mediastinal infection means mediastinitis after cardiac or thoracic surgery.
Table 2 Bacteriological findings and indication of
ciprofloxacin in 98 children
Patients without
CF (n = 77)
Patients with
CF (n = 21)
Bacteriological finding n (%) 40 (51.9) 21 (100)
Presence of P. aeruginosa n (%) 13 (16.9) 20 (95.2)
Mixed bacterial infection n (%) 3 (3.9) 1 (4.8)
Antibiotic combination n (%) 65 (84.4) 21 (100)
Indication for ciprofloxacin
Active infection n (%) 76 (98.7) 21 (100)
Bronchopulmonary n (%) 25 (32.4) 21 (100)
Urinary tract n (%) 8 (10.4) 0
Intra-abdominal infection n (%) 7 (9.1) 0
Bloodstream infection/catheter
infection n (%)
2 (2.6)/4 (5.2) 0
Operative site infection n (%) 5 (6.5) 0
Bone or joint n (%) 4 (5.2) 0
Cerebral n (%) 4 (5.2) 0
Mediastinitis$ n (%) 3 (3.9) 0
Endocarditis n (%) 2 (2.6) 0
Miscellaneous§ n (%) 12 (15.6) 0
Prophylaxis n (%) 1 (1.3) 0
Miscellaneous§:2 BCGitis, 1 Ocular infection, 1 cutaneous infection and 8 fever
in immunocompromised children among whom 4 with current neutropenia.
$: Mediastinal infection means mediastinitis after cardiac or thoracic surgery.
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situation or susceptibility testing, in the presence of an
available alternative enteral or parenteral antibiotic
choice. Finally “unjustified” prescriptions were defined as
ciprofloxacin prescription not indicated according to the
clinical situation, and/or susceptibility results. The latter
two groups defined the inappropriate fluoroquinolone
usage.
For the discharged children, the follow-up and moni-
toring was performed by their respective physician and
adverse events were reported to our mobile team if my-
algia or arthralgia was mentioned by patients.
Data protection was approved by the Institutional Re-
view Board of Necker-Enfants Malades Hospital. No eth-
ical committee approval was required under French
regulations.
Results
A total of 11,268 children were admitted between 1st
December 2007 and 31st May 2008 at the Necker-
Enfants malades hospital in Paris. 98 new ciprofloxacin
prescriptions were collected. Prescriptions mainly origi-
nated from general pediatric wards (22.4%), immuno-
hematology department (20.4%), polyvalent intensive
care units (12.2%), cardiac surgery unit (11.2%), general
surgery (9.2%) and orthopedic surgery (9.2%). Twenty-
one patients with cystic fibrosis and 77 without CF re-
ceived at least one dose of ciprofloxacin during the study
period.
Demographic characteristics and underlying diseases of
the population
The median age of the 98 children receiving ciprofloxacin
was 10 years (1 month – 15 years). 35 were younger than
2 years, 17 were ≥2 and <6 years old, and 46 were ≥6 years
up to puberty onset. The gender ratio was 1.3 (M/F). 45/
98 (45.9%) had an underlying condition, the most frequent
being cystic fibrosis (n = 21, 21.4%), followed by immune
deficiencies such as neutropenia (<500/mm3) or severe
combined immunodeficiency (SCID) (12.2%) or use of any
immunosuppressive agent (12.2%) (corticosteroids, cyclo-
sporine or tacrolimus) because of solid organ transplant (3
hepatic, 2 intestinal and hepatic, 1 intestinal, 1 renal and 1
cardiac) and 4 others (glycogenosis, hemophagocytosis
syndrome, osteopetrosis and Wegener’s granulomatosis).
Type of infections
Sixty-two infections were nosocomially-acquired, twenty-
four were healthcare-associated and thirty-five were com-
munity acquired. The remaining child received ciprofloxacin
for prophylaxis during orthopedic surgery (Table 1).
Table 2 reports the site of infections and the bacterio-
logical findings. In CF patients, the most frequent clinical
indications were P. aeruginosa (95.2%) or methicillin-
resistant S. aureus broncho-pulmonary infection (4.8%).
Table 3 Ciprofloxacin dosages in 98 children
Dose (mg/kg/day) Frequency of administration Adequate
dose* n (%)n Min Max Median Mean (SD) qd b.i.d t.i.d
Patients without CF oral cipro 32 15 50 20 23(7) 1 30 1 31 (96.9)
i.v. cipro 45 10 60 20 23(9) 1 36 8 38 (84..4)
Total 77 10 60 20 23(8) 2 66 9 69 (89.6)
Patients with CF oral cipro 20 30 50 40 37(5) 0 19 1 13 (61.9)
i.v. cipro 1 / / / / 0 1 0 1 (100)
Total 21 30 50 40 37(5) 0 20 1 14 (66.7)
Total 98 10 60 20 26(9) 2 86 10 83 (84.7)
* Adequate dose in patients without CF was considered as 6 to 10 mg/kg/dose intravenous t.i.d. or 10 to 15 mg/kg/dose orally b.i.d. in children with CF, 10 or
15 mg/kg/dose intravenous three times daily or twice daily followed by 20 mg/kg/dose per os twice daily.




With bacteriological finding 23 (100)
P. aeruginosa 23






Only cipro susceptible 12
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In non-CF patients, P. aeruginosa infections represented
16.9% of the ciprofloxacin prescriptions.
Adequacy of ciprofloxacin prescriptions
The median ciprofloxacin’s dosage (Table 3) was 40 mg/
kg/24 h (QR range 30–40 mg/kg/24 h), and 20 mg/kg/
24 h (QR range was 20–30 mg/kg/24 h), in CF and non-
CF patients, respectively.
Among the 98 ciprofloxacin prescriptions, 23 (23.4%)
were considered as “mandatory”, 48 (49.0%) were “alter-
native” and 27 (27.6%) were “unjustified” (Table 4).
Among 23 prescriptions classified as mandatory, 17
children had CF and 6 not. All had microbiologically
documentation with P. aeruginosa (Table 4).
Forty-eight prescriptions were classified as “alterna-
tive”. Among them, 28 had culture results available (6
due to P. aeruginosa and 22 due to other bacteria) and
20 without. All could have received an alternative anti-
biotic (Table 5).
27 were classified as “unjustified” and corresponded to
any ciprofloxacin prescription that was not indicated
according to the clinical situation and/or microbiological
results. Among these 27, 10 had culture results available,
4 due to P. aeruginosa susceptible to all known active
antibiotics and 6 due to another microorganism. All of
these 10 unjustified prescriptions (5 orally and 5 intra-
venously) were not indicated based on the current clin-
ical situation or microbiological results (Table 6).
Side effect of ciprofloxacin
We did not notice any bone/joint short-term side effects
among the 98 children, even 2 weeks after the end of
ciprofloxacin therapy.
Discussion
In our study, 76.6% of ciprofloxacin indications were in-
appropriate, most often (49.0%) because another antibac-
terial could have been considered and 27.6% did not
correspond to validated indications. The American
Table 5 Description of alternative ciprofloxacin prescriptions
Alternative cipro prescription n (%)
With bacteriological finding 28 (58.3)
P. aeruginosa 6
Cystic fibrosis pulmonary infection 3










Site of infection for non P. aeruginosa$ 22
Alternative by another active antibiotic 28
Without bacteriological finding 20 (41.7)
Alternative by another antibiotic 20
Site of infection for non bacteriologically documented infection & 17




CNS = coagulase negative Staphylococcus, MRSA =Methicillin-resistant S. aureus.
¶ 5 CNSs were isolated from hemocultures, of which 2 had endocarditis, 1 catheter related bloodstream infection.
# 2 urinary infection and 1 operative site infection with P. aeruginosa.
£ One child with CF had MRSA pulmonary infection.
* E. cloacae, H. influenzae, M. catarrhalis, K. oxytoca, each.
$ 8 pulmonary, 3 urinary, 3 intra-abdominal, 2 bloodstream, 3 operative site infection and 1 endocarditis, catheter related infection, osteomyelitis each.
& 5 pulmonary, 3 meningitis, 2 mediastinitis, 2 BCGitis and intra-abdominal infection, endocarditis, post-trauma ocular infection, osteomyelitis, urinary each.
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Academy of Pediatrics [6] supports the use of ciprofloxa-
cin in pediatric cystic fibrosis patients with acute pul-
monary exacerbation associated with P. aeruginosa
infection, while in recent years, recommendations have
also included P. aeruginosa osteochondritis, shigellosis,
salmonellosis, and C. jejuni infections, prophylaxis dur-
ing neutropenia, empiric therapy in febrile neutropenic
children with cancer, treatment of patients with
multidrug-resistant Gram-negative bacteremia or menin-
gitis, and combination use with other agents to treat
multidrug-resistant mycobacterial disease. Although a
recent study showed that levofloxacin may represent an
effective therapy [15], the American Academy of
Pediatrics does not recommend it for first-line therapy
of respiratory tract infection in children [10]. The ex-
perience of use FQ in fever with neutropenia or in critic-
ally ill children has been limited. Sideri’s study [16],
including 18 critically ill children, showed that ciproflox-
acin might be a useful option for critically ill children
without CF. More recently, Sung L et al. [17] has meta-
analyzed 740 low-risk fever with neutropenia episodes in
10 studies, which showed 17% to 24% treatment failure
with ciprofloxacin monotherapy or FQ combination
therapy, but no cases of infectious deaths has been
reported and the rates of adverse events were very low.
But in our study, we still considered 4 ciprofloxacin
combination prescriptions for fever and neutropenia as
“unjustified”.
The use of an incorrect dosage was also frequent
among children treated with ciprofloxacin. Indeed, in
our study, 28 (28.6%) received an incorrect ciprofloxacin
dosage. Furthermore, of the 23 pediatric patients in
whom ciprofloxacin was prescribed as mandatory, 9
(39.1%) received an incorrect dose (4 received an exces-
sive dose while 5 an insufficient dose). Sermet-Gaudelus
et al. suggested that an excessive daily dosage was con-
sidered when it was more than 40 mg/kg in non CF pa-
tient and an insufficient dosage was considered when it
was less than 40 mg/kg/d in CF patients and less than
20 mg/kg/d in non CF patients [18]. The likelihood of
Table 6 Description of unjustified ciprofloxacin prescriptions
Unjustified cipro prescription n (%)
With bacteriological finding 10 (37.0)
P. aeruginosa 4
Intravenous cipro 4
Site of infection for P. aeruginosa# 4
Multiply susceptible E. coli 1




Site for non-P. aeruginosa infections$
Unjustified by antibiogram results 6
Unjustified by intravenous cipro in susceptible P. aeruginosa infection 4
Without bacteriological finding 17 (63.0)
Site of non bacteriologically-documented infection 12
Pulmonary 7
Abdominal 2
Catheter related infection 1
Operative site infection 1
Prophylaxis 1





Unjustified by clinical situation 17
Total 27 (100)
# 2 pulmonary and 2 catheter related infection.
$ 2 pulmonary, 2 urinary and intra-abdominal, mediastinitis each.
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FQ drug toxicity may also be affected by inappropriate
FQ prescribing. In fact, higher dose and longer duration
of FQ therapy have both been associated with a greater
risk of adverse events, including emergence of multidrug
resistance [19].
The use of FQ has been limited in pediatric infection
due to their potential side-effects which have been found
to affect cartilage in juvenile animals, resulting in ar-
thropathy [1]. However, in recently controlled, retro-
spective studies, major arthropathy (as observed in
animals) has never been notified in children [4,5]. In
addition, if a musculoskeletal event did occur in the ex-
posed children, it was always minor and always revers-
ible. In recent years, FQ use in children has increased in
the United States, but not in France [3]. Few studies
have evaluated the appropriate use of FQ prescriptions
in children in order to avoid the side effects and their
ecological impact [20]. In our study, we did not notice
any bone/joint short-term side effects among the 98
children, even 2 weeks after the end of ciprofloxacin
therapy, because our observational period was too short
or the cases were too small to evaluate the side effects of
ciprofloxacin in children use.
Our findings suggest that our current patterns of FQ
use can be greatly improved in children in an effort to re-
duce the spread of FQ resistance. Recently, several studies
have showed that about 50%, even up to 70%, of antibiotic
usage in hospitals and in emergency departments were in-
appropriate [21-24], in accordance with our results.
The assistance of a medical microbiologist/infectious dis-
eases specialist in addition to educational presentations as
done in adult’s populations have led to 3 to 4-fold sustained
reduction of inappropriate prescriptions, but also to a sig-
nificant improvement in quality of ciprofloxacin prescrip-
tions [25] in accordance with existing guidelines [22].
The most important situation where we need FQ in
children is cystic fibrosis and P. aeruginosa infection.
Other indications are rare and require individual careful
assessment. The limitations of our study were that it was
an observational monocentric study and was done
within a short period of time. A larger study would have
indeed provided more meaningful information. The dur-
ation of FQ use was not collected in our study.
Conclusion
In our university hospital, only 23.4% of fluoroquinolones
prescriptions were mandatory in children, especially for P.
aeruginosa healthcare associated infection. Looking to the
ecological risk of fluoroquinolones and the increase con-
sumption in children population, we think that a control
program should be developed to control FQ use in chil-
dren. It could be done with the help of an antimicrobial
stewardship team.
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